Trials / Completed
CompletedNCT00751348
Immunogenicity & Safety Study of GSK Biologicals' Combined Measles-mumps-rubella-varicella Vaccine 208136
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 475 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 11 Months – 24 Months
- Healthy volunteers
- Accepted
Summary
This Phase 3b study is being conducted for the purpose of registration of the GSK208136 vaccine in Korea.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | PriorixTM | Subcutaneous administration in left upper arm |
| BIOLOGICAL | VarilrixTM | Subcutaneous administration in right upper arm |
| BIOLOGICAL | Priorix-Tetra® | Subcutaneous injection in left upper arm |
Timeline
- Start date
- 2008-10-01
- Primary completion
- 2010-05-27
- Completion
- 2010-05-27
- First posted
- 2008-09-11
- Last updated
- 2018-06-08
- Results posted
- 2017-04-24
Locations
13 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT00751348. Inclusion in this directory is not an endorsement.